Search

Displaying results 2221 - 2230 of 4345 in total
  1. Drug

    Hexamethonium

    go.drugbank.com/drugs/DB08960
    Experimental

    It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by more specific drugs for most purposes, although it is widely

  2. Drug

    Isoflavone

    go.drugbank.com/drugs/DB12007
    ApprovedInvestigationalWithdrawn

    Isoflavone is a soy phytoestrogen and a biologically active component of several agriculturally important legumes such as soy, peanut, green peas, chick peas and alfalfa . Soybean is an exceptionally rich source of dietary isoflavones, w...

  3. Drug

    Ferric cation

    go.drugbank.com/drugs/DB13949
    ApprovedWithdrawn

    By mass, it is the most common element on Earth.

  4. Drug

    Revumenib

    go.drugbank.com/drugs/DB18515
    ApprovedInvestigational

    It was approved by the FDA in November 2024 for the treatment of leukemia with KMT2A aberrations,[L51868,L51863] becoming the first menin inhibitor to receive FDA approval.

  5. Drug

    Autologous cultured chondrocytes

    go.drugbank.com/drugs/DB10997
    ApprovedInvestigational

    The surgical implantation shows a tolerable safety profile and efficacy up to 4 years, but it is not indicated for patients with osteoarthritis.

  6. Drug

    Nilutamide

    go.drugbank.com/drugs/DB00665
    ApprovedInvestigational

    Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors).

    Products: Anandron Tab 50mg
  7. Drug

    Aprocitentan

    go.drugbank.com/drugs/DB15059
    ApprovedInvestigational

    [A263386,L50261] Aprocitentan was approved by the FDA in March 2024 for the treatment of hypertension in patients inadequately controlled with standard therapy.

  8. Drug

    Sotrovimab

    go.drugbank.com/drugs/DB16355
    ApprovedInvestigational

    [L34425, L34430, L34440] However, in April 2022, the FDA removed the EUA for sotrovimab due to the rising COVID-19 cases caused by the Omicron BA.2 sub-variant, where the drug is ineffective.

  9. Drug

    Biomed 101

    go.drugbank.com/drugs/DB05851
    Investigational

    Biomed 101 binds to the leukotriene B4 receptor, but does not affect interleukin-2 antitumor activity.

  10. Drug

    Acadesine

    go.drugbank.com/drugs/DB04944
    Investigational

    It is being developed jointly by PeriCor and Schering-Plough. Acadesine has been granted Orphan Drug Designation for B-CLL in the EU.